As far as we know, CD8+ T cells are the major “killer” in anti-tumor immunity, therefore, in order to maximize the antitumor potential of SLP vaccine-induced CD8+ T cell response, the optimal adjuvants are in the need for vaccine development. Here, CD8A is linked to neoplasm.